---
title: "\"Review\" of the Top 5 Strongest and Weakest Stocks in the National Index for the First Half of 2025 (Table)"
description: "Summary of the performance of the National Index in the first half of 2025: The five strongest stocks are Xiaomi-W (+73.8%), CSPC PHARMA (+61.1%), Kuaishou-W (+53.1%), JD HEALTH (+53.0%), and NetEase-"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/246635110.md"
published_at: "2025-06-30T09:23:31.000Z"
---

# "Review" of the Top 5 Strongest and Weakest Stocks in the National Index for the First Half of 2025 (Table)

> Summary of the performance of the National Index in the first half of 2025: The five strongest stocks are Xiaomi-W (+73.8%), CSPC PHARMA (+61.1%), Kuaishou-W (+53.1%), JD HEALTH (+53.0%), and NetEase-S (+52.5%); the five weakest stocks are Haier Smart Home (-18.4%), Meituan-W (-17.4%), Trip.com-S (-15.6%), New Oriental-S (-13.9%), and Shenzhou International (-10.0%). The National Index has accumulated an increase of 1,388 points, a rise of 19.0%, closing at 8,678 points

Top 5 Strongest Stocks in the National Index for the First Half of 2025:

Stock │ Price Change in the First Half

Xiaomi-W (01810.HK) │ +73.8%

CSPC PHARMA (01093.HK) │ +61.1%

Kuaishou-W (01024.HK) │ +53.1%

JD HEALTH (06618.HK) │ +53.0%

NetEase-S (09999.HK) │ +52.5%

Top 5 Weakest Stocks in the National Index for the First Half of 2025:

Stock │ Price Change in the First Half

Haier Smart Home (06690.HK) │ -18.4%

Meituan-W (03690.HK) │ -17.4%

Trip.com-S (09961.HK) │ -15.6%

New Oriental-S (09901.HK) │ -13.9%

Shenzhou International (02313.HK) │ -10.0%

In summary, the National Index increased by 1,388 points or 19.0% in the first half of 2025, closing at 8,678 points

### Related Stocks

- [06618.HK - JD HEALTH](https://longbridge.com/en/quote/06618.HK.md)
- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)
- [09901.HK - NEW ORIENTAL-S](https://longbridge.com/en/quote/09901.HK.md)
- [02313.HK - SHENZHOU INTL](https://longbridge.com/en/quote/02313.HK.md)
- [01024.HK - KUAISHOU-W](https://longbridge.com/en/quote/01024.HK.md)
- [09999.HK - NTES-S](https://longbridge.com/en/quote/09999.HK.md)
- [06690.HK - HAIER SMARTHOME](https://longbridge.com/en/quote/06690.HK.md)
- [03690.HK - MEITUAN](https://longbridge.com/en/quote/03690.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| China tightens oversight of online ticket platforms, targets paid priority purchase claims | The Beijing Municipal Administration for Market Regulation has conducted interviews with 12 major online ticket platform | [Link](https://longbridge.com/en/news/275689507.md) |
| CICC Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF) | CICC has reaffirmed its Buy rating for CSPC Pharmaceutical Group (CHJTF) with a price target of HK$12.00. Additionally,  | [Link](https://longbridge.com/en/news/274393834.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.